We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Mylan Can't Duck Securities Fraud Suit, Investors Say

Law360, New York (August 11, 2017, 7:51 PM EDT) -- Investors in EpiPen maker Mylan NV have pushed back against the pharmaceutical company’s bid to toss their securities fraud proposed class action, telling a New York federal court that Mylan hasn’t even challenged two of the categories of misstatements alleged in their complaint.

The investors said on Tuesday that those allegedly misleading omissions — about the government’s communication with and subsequent investigation of Mylan over its classification of EpiPen as a generic drug — will now move forward as a result, while the rest of Mylan’s...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.